Study design (if review, criteria of inclusion for studies)
Controlled: Yes.1 Randomised: Yes.2 Open: No.3 Single blind: No.4 Double blind: Yes.5 Parallel group: No.6 Cross over: No
Participants
Subjects (male or female) 6 years of age and older with stable CF disease, FEV1 value >40% and <90% of predicted
Interventions
The efficacy and pharmacodynamics (PD) of ELX/TEZ/IVA
Outcome measures
Primary end point(s): Absolute change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1) through Week 24